Skip to main content
SpringerLink
Log in

Cholinergic approaches to the treatment of progressive supranuclear palsy

  • Conference paper
Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURAL SUPPL,volume 42))

Summary

In spite of the severe loss of cholinergic neurons in the brains of patients with progressive supranuclear palsy (PSP), marginal or null benefits are seen in clinical trials after the administration of physostigmine, a cholinesterase inhibitor, or RS-86, a cholinergic agonist. The possible role of cholinergic therapy in PSP is reevaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, Hauw JJ, Baron JC, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 191–206.

    Google Scholar 

  • Atack JR, Litvan I, Thal LJ, May C, Rapaport SI, Chase TN (1991) Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 54: 832–835.

    Article  PubMed  CAS  Google Scholar 

  • Brandel JP, Hirsch EC, Malessa S, Duyckaerts C, Cervera P, Agid Y (1991) Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 41: 25–31.

    Article  PubMed  CAS  Google Scholar 

  • Brown J (1958) Some test of decay theory of immediate memory. Q J Exp Psychol 39: 15–22.

    Google Scholar 

  • Buschke H, Altman Fuld P (1974) Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019–1025.

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17: 124–136.

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin R (1992) Clinical diagnosis. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, pp 15-33.

    Google Scholar 

  • Foster NL, Aldrich MS, Bluemlein MS, White RF, Berent S (1989) Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39: 257–261.

    Article  PubMed  CAS  Google Scholar 

  • Giacobini E (1991) The second generation of cholinesterase inhibitors: pharmacological aspects. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 247–262.

    Google Scholar 

  • Grafman J, Litvan I, Gomez C, Chase TN (1990) Frontal lobe function in progressive supranuclear palsy. Arch Neurol 47: 553–558.

    Article  PubMed  CAS  Google Scholar 

  • Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C (1990) Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer’s disease and aging. Neurosci Lett 119: 182–186.

    Article  PubMed  CAS  Google Scholar 

  • Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84: 5976–5980.

    Article  PubMed  CAS  Google Scholar 

  • Jellinger K (1988) The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 51: 540–543.

    Article  PubMed  CAS  Google Scholar 

  • Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y (1991) Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 41: 25–30.

    Article  PubMed  CAS  Google Scholar 

  • Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.

    Article  PubMed  CAS  Google Scholar 

  • Kertzman C, Robinson DL, Litvan I (1990) Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47: 1346–1350.

    Article  PubMed  CAS  Google Scholar 

  • Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (1989) Falls and Parkinson’s disease. Clin Neuropharmacol 12: 98–105.

    Article  PubMed  CAS  Google Scholar 

  • Litvan I, Gomez C, Atack JR, Gillespie M, Kask A, Mouradian MM, Chase TN (1989) Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26: 404–407.

    Article  PubMed  CAS  Google Scholar 

  • Litvan I, Chase TN (1992) Traditional and expeRImental therapeutic approaches. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, New York, pp 254–269.

    Google Scholar 

  • Malessa S, Hirsch EC, Cervera P, Javoy-Agid F, Duyckaerts C, Hauw JJ, Agid Y (1991) Progressive supranuclear palsy: loss of choline acetyltransferase-like im-munoreactive neurons in the pontine reticular formation. Neurology 41: 1593–1597.

    Article  PubMed  CAS  Google Scholar 

  • Marchi M, Besana E, Codignola A (1991) Presynaptic cholinergic mechanisms in human cerebral cortex of adult and aged patients. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 92–97.

    Google Scholar 

  • Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y (1988) D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.

    Article  PubMed  CAS  Google Scholar 

  • Potter LT (1987) Muscarinic receptors in the cortex and hippocampus in relation to the treatment of Alzheimer’s disease. In: Cohen S, Sokolovsky M (eds) International symposium on muscarinic cholinergic mechanisms. Freud Publishing Ltd, London, pp 294–301.

    Google Scholar 

  • Rafal RD, Posner MI, Friedman JH, Inhoff A, Bernstein E (1988) Orienting of visual attention in progressive supranuclear palsy. Brain 111: 267–280.

    Article  PubMed  Google Scholar 

  • Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, Lheureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.

    Article  PubMed  CAS  Google Scholar 

  • Ruberg M, Hirsch E, Javoy-Agid F (1992) Neurochemistry. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, New York, pp 89–109.

    Google Scholar 

  • Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy, nuclear dystonia, and dementia. Arch Neurol 10: 333–359.

    Article  PubMed  CAS  Google Scholar 

  • Thal LJ, Fuld PA, Masur DM, Sharpless NS (1983) Oral physostigmine without lecithin improves memory in Alzheimer’s disease. J Am Geriatr Soc 37: 42–48.

    Google Scholar 

  • Tagliavini F, Pilleri G, Gemignani F, Lechi A (1983) Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol 61: 157–160.

    Article  PubMed  CAS  Google Scholar 

  • Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87: 7050–7054.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroepidemiology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

    Dr. I. Litvan

  2. Neuroepidemiology Branch, National Institutes of Neurological Disorders and Stroke, Federal Bldg., Rm. 714, Bethesda, MD, 20892, USA

    Dr. I. Litvan

Authors
  1. Dr. I. Litvan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurology Service, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain

    E. Tolosa

  2. Neurology Service, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA

    R. Duvoisin

  3. Neurological Tissue Bank, Faculty of Medicine, University of Barcelona, Spain

    F. F. Cruz-Sánchez

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Wien

About this paper

Cite this paper

Litvan, I. (1994). Cholinergic approaches to the treatment of progressive supranuclear palsy. In: Tolosa, E., Duvoisin, R., Cruz-Sánchez, F.F. (eds) Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy. Journal of Neural Transmission. Supplementa, vol 42. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6641-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6641-3_21

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82541-9

  • Online ISBN: 978-3-7091-6641-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation